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Abstract  
Undifferentiated pleomorphic sarcoma of bone (UPSb), is a rare primary bone sarcoma 
that lacks a specific line of differentiation. There is very little information about the genetic 
alterations leading to tumourigenesis or malignant transformation. Distinguishing between 
UPSb and other malignant bone sarcomas, including dedifferentiated chondrosarcoma 
and osteosarcoma, can be challenging due to overlapping features. To explore the 
genomic and transcriptomic landscape of UPSb tumours, whole-exome sequencing 
(Giacomini,  #274) and RNA Sequencing (RNA-Seq) were performed on UPSb tumours. 
All tumours lacked hotspot mutations in IDH1/2 132 or 172 codons, thereby excluding the 
diagnosis of dedifferentiated chondrosarcoma. Recurrent somatic mutations in TP53 were 
identified in 4/14 samples (29%). Moreover, recurrent mutations in histone chromatin 
remodelling genes, including H3F3A, ATRX and DOT1L, were identified in 5/14 samples 
(36%), highlighting the potential role of deregulated chromatin remodelling pathways in 
UPSb tumourigenesis. The majority of recurrent mutations in chromatin remodelling genes 
identified here are reported in COSMIC, including the H3F3A G35 and K36 hotspot 
residues. Copy number alteration analysis identified gains and losses in genes that have 
been previously altered in UPSb or UPS of soft tissue. Eight somatic gene fusions were 
identified by RNA-Seq, two of which, CLTC-VMP1 and FARP1-STK24, were reported 
previously in multiple cancers. Genomic characterization of these fusions revealed 
potential tumour suppressing or oncogenic roles. Hierarchical clustering analysis, using 
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RNA-Seq data, distinctly clustered UPSb tumours from osteosarcoma and other 
sarcomas, thus molecularly distinguishing UPSb from other sarcomas. RNA-Seq 
expression profiling analysis and quantitative RT-PCR showed an elevated expression in 
FGF23 which can be a potential molecular biomarker in UPSb.   To our knowledge, this 
study represents the first comprehensive WES and RNA-Seq analysis of UPSb tumours 
revealing novel protein-coding recurrent gene mutations, gene fusions and identifying a 
potential UPSb molecular biomarker, thereby broadening the understanding of the 
pathogenic mechanisms and highlighting the possibility of developing novel targeted 
therapeutics.  
Keywords: whole exome sequencing, RNA sequencing, undifferentiated pleomorphic 
sarcoma of the bone, chromatin remodelling genes, gene fusions, sarcomas, FGF23, 
CNV, gene expression and hierarchical clustering analyses.  
 
Introduction  
Undifferentiated high-grade pleomorphic sarcoma of bone (UPSb) is a rare aggressive 
bone sarcoma that lacks a specific line or pattern of differentiation [1]. These tumours 
represent <2% of all primary malignant bone neoplasms and rarely occur in young adults 
[1,2]. Tumours commonly arise in long bones of lower extremities, particularly the femur 
followed by tibia and humerus, with a metastatic rate of at least 50%, especially to lungs 
[2,3]. The morphological appearance of the tumours is heterogeneous, consisting of 
atypical spindle and pleomorphic cells that lack matrix production. As UPSb is a diagnosis 
exclusion, thorough and extensive sampling of the tumour to rule out osteosarcoma or de-
differentiated chondrosarcoma is mandatory [4]. This might pose diagnostic difficulties, 
particularly in a limited biopsy sample. The recommended treatment generally involves 
neoadjuvant therapy followed by wide surgical excision [5]. The chemosensitivity and 
survival rate of UPSb are similar to osteosarcoma but distinction from dedifferentiated 
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chondrosarcoma, which has a dismal prognosis, is important [5]. To date, there are no 
molecular studies or stringent diagnostic criteria to distinguish between these bone 
sarcomas. The genetics of UPSb is poorly understood. Previous studies have reported low 
frequency of TP53 mutations, MDM2 amplification [6], and various genomic gains and 
losses, including CDKN2A, RB1 and TP53 [2]. Nevertheless, no extensive high-throughput 
studies have been conducted to achieve a comprehensive understanding of the aetiology 
of these tumours. To gain further comprehensive insights into the molecular landscape 
and pathogenic mechanisms of UPSb, we performed integrative analysis using whole 
exome sequencing (WES) and RNA sequencing (RNA-Seq).  
Materials and methods 
Tumour samples 
A retrospective search of the pathology database at the Royal Orthopaedic Hospital for 
resected samples of UPSb was carried out. In total, fourteen cases with the diagnosis of 
UPSb were identified (additional details in materials and methods supplementary 
material).  
Whole exome sequencing and copy number alteration analysis 
DNA from fresh frozen and FFPE (10 x 10µm sections) tissues was extracted and purified 
using the DNA Isolation (Roche Diagnostic Ltd, UK) and Arcturus PicoPure DNA 
Extraction kits (ThermoFisher Scientific, UK), respectively, following the manufacturer’s 
instructions. A total of 1-3 µg of DNA from 12 tumours and 9 corresponding normals were 
sent to Oxford Gene Technology (OGT, Oxford) for WES. Exons were captured using the 
Agilent SureSelect Human All Exon V5 kit (Agilent, Santa Clara, USA), following 
manufacturer's protocol, and were massively sequenced (100-bp paired-end) using the 
Illumina HiSeq 2000 platform (Illumina, San Diego, CA). Two tumours and one 
corresponding normal were exome-sequenced at SMCL Next Generation Sequencing 
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(NGS) Hub (Cambridge, UK). Exons were captured by Illumina Nextera Rapid Capture 
Exome kit and sequenced using Illumina HiSeq 4000, generating 2 X 150 bp reads. 
Additional information is in materials and methods supplementary material. 
CNV analysis (from WES data) was performed on ten normal-paired UPSb tumours, using 
CNVkit, applying the tool’s default settings https://cnvkit.readthedocs.io/en/stable/).   
 
 
RNA Sequencing experiment  
Total RNA from eight fresh frozen tissues was extracted using either standard TRIzol-
chloroform method or Qiagen RNeasy Mini kit (Qiagen, Manchester, UK) following the 
manufacturer’s instructions. The quality and concentration of RNA was assessed using 
Agilent 2100 bioanalyzer (Agilent Technologies, Santa Clara, CA). A total of 50-100ng of 
DNase-treated RNA from each tumour was massively sequenced at the Genomics 
Birmingham facility (Institute of Cancer & Genomic Sciences, University of Birmingham). 
Additional information is in materials and methods supplementary material. 
RNA-Seq differential gene expression profiling and hierarchical clustering analyses  
The 149 RNAseq samples from the CINSARC dataset [1] were retrieved from the 
Sequence Read Archive Bioproject PRJNA282597 
(https://trace.ncbi.nlm.nih.gov/Traces/sra/sra.cgi?study=SRP057793)  and 16 
osteosarcoma samples were randomly chosen from the SRA bioproject PRJNA345424 
(https://trace.ncbi.nlm.nih.gov/Traces/sra/sra.cgi?study=SRP090849) [2]. Gene expression 
values were extracted by Kallisto v0.42.5 [3] with GRCh38 release 79 genome annotation 
and transformed into log2(tpm+2) prior to sample aggregation and normalization using the 
quantile method of the limma R package, within the R version 3.1.2 [4]. Clustering was 
computed using the Cluster v2.0.3 package. Pairwise comparisons of expression profiles 
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were performed using F-Test variance comparison prior to Student’s t-Test statistics with a 
Bonferroni correction. The pairwise comparisons of UPSb versus all other tumours were 
performed iteratively with 20 random sampling of 10 samples from the larger group.  Gene 




Exome sequencing identifies recurrent mutations in TP53 and histone remodelling 
genes  
To investigate the mutational landscape of UPSb, WES was performed on 14 tumours and 
ten matched-normal tissue samples, aiming to achieve a coverage depth of at least 50X in 
each sample. Using stringent criteria to call high-confidence somatic mutations (see 
materials and methods), 794 single nucleotide variants (SNVs), representing the majority 
of mutations (85%), and 138 indels (insertions and deletions) were detected, 
corresponding to a median of 2.2 mutations (range from 0 to 10) per coding megabase 
(Supplementary material, Table S1 & Figure S1). This overall somatic mutation burden is 
comparable with a low mutation burden average of 1.06 per megabase identified in 206 
soft tissue sarcomas, including 44 UPS of soft tissue (UPSst) [12]. Somatic SNVs 
comprised of: 748 nonsynonymous substitutions, 33 nonsense and 13 splice sites 
mutations. A total of 123 SNVs and indels were validated by Sanger sequencing, 
achieving 96.6% validation rate. To identify potential cancer driver genes, we focused on 
somatic recurrent genes that are mutated in more than one tumour. A total of 31 recurrent 
genes harbouring heterozygous somatic mutations were identified in 2/14 (14%) tumours, 
except for TP53 which was mutated in 4/14 (29%) samples (Figure 1A & Figure 2A). The 
majority of recurrent genes were confirmed by Sanger sequencing (examples in 
Supplementary material, Figure S2). All four TP53 somatic missense substitutions 
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(R158H, V216M, Y236C C242G) are described ‘somatic’ in COSMIC database and 
predicted deleterious by two independent in-silico tools (Supplementary material, Table 
S2). V216M missense substitution has been reported previously in a UPSb tumour with a 
progressive disease behaviour [6]. In addition to mutations in TP53 gene, which 
participates in the integrity of histone remodelling complexes [13], recurrent somatic 
mutations in histone remodelling genes including H3F3A, ATRX and DOT1L were 
detected in 5/14 (36%) samples, suggesting a potential role of defective chromatin 
remodelling genes in UPSb tumourigenesis (Figure 2 B, C & D, Supplementary material, 
Table S2). Somatic G34V missense substitution and V35_K36insL in-frame insertion in the 
previously known H3F3A hotspot residues were identified in two UPSb tumours. Mutations 
in ATRX and DOT1L were missense substitutions. One ATRX mutation, E351V, is 
reported somatic in COSMIC database. We identified two mutations in DOT1L, G307V and 
Q595H occurring in Histone-lysine N-methyltransferase catalytic DOT1 domain and 
STAT1 binding motifs, respectively. To further investigate the cancer-related genes, all 
recurrent candidate genes were assessed against COSMIC Cancer Gene Census (CCGC) 
and InTOgen cancer driver genes databases. Seven genes (TP53, ATRX, H3F3A, ZFHX3, 
CSMD3, PRPRT, TRIO) were classified as cancer drivers (Figure 1A). Eight recurrent 
genes (TP53, ATRX, DOT1L, GCGR, COL4A2, KCNQ3, PKLR, SLC12A1) were identified 
as potential druggable genes by the drug–gene interaction database (DGIdb) (Figure 1A). 
Somatic copy number alteration analysis using WES data   
Somatic copy number alteration analysis (CNV) was performed on ten normal-tumour 
UPSb samples. Supplementary material, Figure S3 shows the overall somatic CNV 
heatmap of UPSb tumours. In comparison with a study Niini et al. (Niini, 2011 #265) that 
assessed the CNV profile in UPSb, we comparingly identified CNV alterations in the 
following genes: ING1, CGK4, MDM2, MYC, PDGFRA, KIT, KDR, PDGFA, PDGFB, 
VEGFA (Supplementary material, Table S3). We also found somatic CNV losses in RB1 in 
	 8	
5/10 (50%) cases, gains and losses in VGLL3 and CDKN2A, losses in YAP1 as well as 
loss and gain in CCNE1 (Supplementary material, Table S3), genes that been previously 




RNA-Seq identifies two previously reported and six novel gene fusions  
RNA-Seq was conducted on eight tumours, achieving a mean of 59,722,616 reads with 
90.07% successful alignment rate to reference genome. Using two bioinformatic fusion 
callers and following a series of filtering steps (see materials and methods), eight gene 
fusion candidates were identified in four tumours, two of which were previously described 
in the literature (CLTC-VMP1 and FARP1-STK24) [7,15] whereas the remaining fusions 
are novel (Figure 1B & Supplementary material, Table S4). In addition, the previously 
reported CTSC-RAB38 read-through chimera in cancer and non-cancer tissues [16] was 
identified in 2/8 tumours (25%). Using RT-PCR, all eight fusions were detected in the 
tumour cDNA but not in corresponding normal tissue samples, suggesting that the fusions 
are highly tumour-specific. Focusing on gene fusions with potential druggability and/or 
involvement in tumourigenesis, genomic analysis breakpoints using LR-PCR were 
performed on five out of the eight fusions to determine the precise genomic breakpoints 
(Supplementary material, Table S4). Using LR-PCR, all five fusions were genomically 
characterised and validated in the tumour DNA but were not detected in corresponding 
normal tissues, confirming the somatic status of the fusions. The APOL1-MYH9 and 
PKNOX2-MMP20 occur as a result of paracentric chromosome inversion whereas ASAP2-
ADAM17 forms by an interstitial chromosomal deletion of ~97 kilobase. The two gene 
fusions previously reported in other cancer samples and cell lines are CLTC-VMP1 and 
FARP1-STK24 (Supplementary material, Figure S4 & S5). CLTC-VMP1 has been 
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described previously in BT-549 and HCC1954 breast cancer cell lines [7], hypopharynx 
tumour [17] and large-cell lung carcinoma [18]. The CLTC-VMP1 gene fusion results from 
joining the first 14 exons of CLTC to the last two exons of VMP1 (Supplementary material, 
Figure S4 A & B). Genomic breakpoint analysis revealed a ~158 kilobase interstitial 
deletion within CLTC and VMP1 genes, leading to a complete deletion of PTRH2 gene 
residing within the fusion gene partners (Supplementary material, Figure S4 C & D). The 
CLTC-VMP1 chimeric transcript is an out-of-frame fusion, for which the predicted 
translation product includes the first 764 amino acids of CLTC gene that extends to the 
beginning of exon 11 of VMP1 (at codon 324) and reaching a premature stop codon after 
75 amino acids (Figure 3A). The FARP1-STK24 chimeric fusion is formed as a result of a 
~219 kilobase interstitial deletion within gene partners, linking the first three and five exons 
of FARP1 and STK24, respectively (Supplementary material, Figure S5 A, B, C & D). The 
chimeric transcript is in-frame, consisting of the first 88 and 211 amino acid residues of 
FARP1 and STK24, respectively (Figure 3B). In FARP1-STK24, the majority of the STK24 
protein kinase domain is retained yet missing the STK24 regulatory region (Figure 3B). 
This gene fusion has been previously described in an invasive breast cancer tumour [15]. 
To infer the potential biological relevance of the novel chimeric transcripts, gene fusion 
partner genes were checked against CCCG and InTOgen database, classifying CLTC and 
MYH9 (in APOL1-MYH9) as ‘cancer driver genes’ (Figure 1B). DGIdb identified three 
drug-gene interactions for three fusions partner genes (underlined) in the following gene 
fusions: FARP1-STK24, ASAP2-ADAM17, PKNOX2-MMP20 (Figure 1B).  
Hierarchical clustering and expression profiling analyses using RNA-Seq data 
Using RNA-Seq data, unsupervised hierarchical clustering analysis of UPSb tumours, 
other sarcomas and SRP090849 datasets distinctly clustered the UPSb tumours together 
in two groups, UPSb-G1 and UPSb-G2, thus molecularly distinguishing UPSb from 
osteosarcoma and other sarcomas (Figure 4A). Checking the clinicopathological 
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information of the two UPSb groups, UPSb-G2 (T1, T2, T5, T6) primarily has spindle cell 
morphology, in comparison with UPSb-G1 (T9, T10, T13, T14), which shows a mixture of 
spindle, pleomorphic and epithelioid morphology (an example of each group in 
Supplementary material, Figure S6). Supervised expression analysis of UPSb versus other 
sarcoma subtypes highlighted FGF23, fibroblast growth factor 23, as a specifically 
expressed gene in UPSb tumours (Figure 4B). David Gene Ontology analyses of specific 
UPSb genes identified a strong enrichment of immune response genes, suggesting their 
potential involvement in UPSb tumourigenesis (Figure 4C).  
Confirmation of elevated FGF23 expression in UPSb using quantitative RT-PCR 
To confirm the elevated expression of FGF23 by RNA-Seq, quantitative RT-PCR was 
carried out on four UPSb tumours and four normal tissue controls. An elevated expression 
of FGF23 was significantly observed in all tumours, comparing to low FGF23 expression 
levels in normal samples (p-value=0.0286) (Supplementary material, Figure S7).  
 
Discussion 
In this study, we examined the somatic genetic alterations present in UPSb tumours using 
WES and RNA-Seq technologies as well as comparing transcriptomic profiles of UPSb 
with other sarcomas. We performed WES on 14 tumours and focused on genes that are 
altered in more than one tumour, identifying a total of 31 recurrent genes. TP53 was the 
most frequently mutated gene (29% of tumours). In 36% of the tumours, we identified 
mutations in chromatin remodelling genes (H3F3A, ATRX, DOT1L) which have not been 
previously described in the UPSb subtype. A significant co-occurrence of G34 H3F3A 
mutation with ATRX/DAXX and TP53 mutations has been observed in nearly 100% of 
glioblastoma tumours [14]. Notably, no correlation of H3F3A mutations was observed in 
UPSb tumours harbouring TP53, ATRX or DOT1L mutations.  
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Somatic CNV analysis on ten tumours revealed alterations in genes that have been 
previously implicated in UPSb (Niini, 2011 #265) and UPSst (Cancer Genome Atlas 
Research Network. Electronic address, 2017 #271), including MDM2, ING1, RB1, 
CDKN2A, VGLL3, YAP1 and CCNE1. Deep deletions in RB1 and CDKN2A has been 
identified recently in 16% and 20% of UPSst, respectively; whereas high-level 
amplifications were present in VGLL3, YAP1 and CCNE1 in 11%, 3% and 10% of UPSst 
(Cancer Genome Atlas Research Network. Electronic address, 2017 #271).  
Heterozygous R132 and R172 hotspot point mutations in IDH1 and IDH2, respectively, are 
commonly present in 61-87% of chondrosarcoma cases, including dedifferentiated 
chondrosarcoma [4,19]; whereas, these changes are absent in 222 osteosarcoma 
samples [20]. In an earlier study by Chen et al. [4], we investigated the IDH1/2 mutation 
status in the 14 UPSb tumours used in this study and found no R132 and R172 mutations 
in any tumour, ruling out a diagnosis of dedifferentiated chondrosarcoma. Unlike the 
established association of IDH1/2 in chondrosarcoma, the somatic genomic profile of 
osteosarcoma is complex and involves multiple genes, mainly TP53 and RB1 [21]. These 
genes are well-known cancer driver genes implicated in multiple cancers and therefore 
cannot be sensitively used to exclude the diagnosis of osteosarcoma. 
The TP53 gene is the most frequently mutated gene in various human cancers and 90% of 
TP53 mutations are missense changes with potential gain-of-function characteristics 
[22,23]. Previously, TP53 mutations were identified in 22% of UPSb tumours by 
conventional PCR and Sanger sequencing [6].  In this study, using massive-parallel 
sequencing for the first time on this tumour subtype, four TP53 missense mutations 
(R158H, COSMIC ID: COSM1640853; V216M, COSM10667; Y236C, COSM10731; 
C242G, COSM3717645), all occurring in the DNA-binding domain of p53 protein (Figure 
2A), were indentified.  Mutations in the p53 DNA-binding domain can reduce the protein’s 
binding specifically to DNA sequence motifs in p53-regulated genes. The R158H, V216M 
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and Y236C mutations are reported among the 50 most common somatic missense 
mutations in TP53, highlighting their potential pathological role in tumourigenesis [22]. We 
could not find significant differences in the total number of mutations in samples 
harbouring TP53 mutations (n=4) comparing to the remaining samples (n=10). 
Correlations between TP53 mutations and clinical implications are difficult to establish due 
to the clinical heterogeneity of the patients and small sample size; hence, additional 
investigations to elucidate their prognostic information are required.  
Recurrent mutations in H3F3A, ATRX and DOT1L were detected in 5/14 tumours. Highly 
specific cancer-driving hotspot mutations in H3F3A (G34) and H3F3B (K36) were identified 
in 92% of giant cell tumour of the bone and 95% of chondroblastoma cases [24]. In this 
study, we identified recurrent somatic mutations (G34V, COSM502595 and V35_K36insL, 
COSM5574356) in H3F3A affecting the previously reported amino acid residues (Figure 
2B). These hotspot sites are well-conserved amino acid residues of the amino-terminus tail 
that undergoes post-translational modifications [14]. Lysine 36 is a principal methylation 
site that typically promotes gene transcription when methylated or acetylated [14]. Histone 
3.3 lysine to methionine substitution (K36M) reduces the methylation of lysine residue 
through inhibition of SET domain-containing enzymes [25].  This reduction of methylation 
at K36 was also observed in cell lines carrying the G34V substitution [25]. Since 
V35_K36insL is an-frame insertion and not a methionine substitution, further investigations 
will be necessary to elucidate any pathogenic mechanism of this in-frame insertion.  
H3F3A/H3F3B driver mutations were described in giant cell tumour of the bone and 
chondroblastoma which are considered benign tumours or benign but locally aggressive 
tumours, respectively [24,26] as well as in malignant giant cell tumour of the bone [27,28]. 
A recent study by Amary et al. [27] identified H3F3A G34 substitutions in 13/385 (3.37%) 
of primary malignant bone tumours, classified as either osteosarcoma or malignant giant 
cell tumour of bone. In this study, we report recurrent H3F3A alterations in 2/14 (14.3%) 
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UPSb tumours, a higher percentage than in previously reported malignant tumours, with 
the caveat of a smaller cohort size. Hence, the possibility of a malignant phenotype or 
evolution should be considered in tumours harbouring H3F3A alterations.   
ATRX is a member of the SWI/SNF2 (SWItch/Sucrose Non-Fermentable) ATP-dependent 
chromatin remodelling protein complex [29] which regulates the expression of thousands 
of genes through remodelling of chromatin structure [30,31]. ATRX has an established role 
in the carcinogenesis of multiple cancers including gliomas [29], small cell lung cancers 
[32] and six adult soft tissue sarcomas (including UPS, leiomyosarcoma, dedifferentiated 
liposarcoma) [12]. Studies have demonstrated a regulational role of ATRX, along with 
DAXX (death domain-associated protein) and other histone chaperone complex proteins, 
in the enrichement of histone H3.3 in telomeres and heterochromatin regions [33,34]. 
Dysfunction ATRX/DAXX is associated with the alternative lengthening of telomeres (ALT), 
a phenomenon observed in 10-15% of cancers of mesenchymal origin (e.g. UPSb) 
resulting in widespread genomic destabilisation [35,36].  In this study, we identified two 
missense mutations in ATRX: S2109I and E351V (COSMIC ID: COSM6608613) occurring 
in the Helicase/ adenosine triphosphatase (ATPase) conserved C-terminus and Enhancer 
zeste homologue 2 (EZH2) interacting region of the ATRX protein, respectively (Figure 
2C). The helicase/ATPase subunit is the catalytic core of ATRX protein [37] which, along 
with other SNF2 proteins, is involved in ATP hydrolysis responsible for chromatin structural 
conformations [38]. The ATRX EZH2 interaction region is involved in the interaction of 
ATRX with (polycomb repressive complex 2) PRC2 protein complex, including EZH2 
catalytic subunit [39,40]. Although further studies are required, mutations in these two 
functionally important domains disrupt ATRX protein function, affecting the integrity of the 
chromatin structure. PRC2/EZH2 inhibitors are currently in clinical trials [39,41]; however, 
the complex and dual oncogenic and tumour-suppressing role of PRC2 in cancers 
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requires detailed mechanistic insights before establishing the efficacy of these inhibitors 
[39].  
In the second part of this study, we aimed to identify genome-wide gene fusions arising 
from chromosomal aberrations in eight UPSb tumour using RNA-Seq. A total of eight 
highly tumour-specific gene fusions were validated by RT-PCR, five of which were 
genomically characterised by LR-PCR. We identified two gene fusions previously reported 
in other cancers, CLTC-VMP1 and FARP1-STK24.  
The CLTC-VMP1 gene fusion is identified in T13, lacking any WES alterations in TP53 or, 
H3F3A, ATRX, DOT1L chromatin remodelling genes. The cDNA breakpoint of CLTC 
identified here is different to those previously reported; however, the breakpoint position in 
VMP1 in UPSb is the same as reported for other tumours. The genomic interstitial deletion 
at 17q23.1 locus, revealed by genomic breakpoint analysis, leads to a complete deletion of 
PTRH2 gene and a loss of six repeats of Clathrin heavy chain/VPS and four 
transmembrane helices of CLTC and VMP1, respectively (Figure 3A). The Clathrin protein 
is involved in chromosome segregation and Golgi reassembly during mitosis and protein-
protein interactions [45]. Rearrangements involving CLTC-PTRH2-VMP1 locus have been 
observed in multiple tumour types, including glioblastoma, lung cancer, breast cancer and 
leukaemias [7]. VMP1 encodes an autophagy-related protein that promotes apoptosis in 
pancreatic cancer cells [46]. PTRH2 is a mitochondrial protein that induces apoptosis by 
regulation of the function of Groucho family transcriptional regulators [47].  Knockdown of 
PTRH2/BIT1 in adherent cells decreased cell survival and promoted staurosporine and 
serum-deprivation apoptosis of cells, consistent with tumour suppressive role [48]. 
Altogether and as Giacomini et al. [7] suggested, the rearrangement involving CLTC-
PTRH2-VMP1 and the CLTC-VMP1 gene fusion being out-of-frame are indicative of a 
disruption of the tumour suppressor activity. 
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The FARP1-STK24 gene fusion is formed by joining the two gene partners in opposing 
(sense-to-antisense) orientations, known as 5’-to-5’ gene fusions Figure 3B). 5’-5’ gene 
fusions have previously been reported in breast cancers [49]. Since the 5’ transcription 
regulatory apparatus of both FARP1 and STK24 is retained, theoretically, both sense 
(FARP1) and antisense (STK24) genes can start transcription that extends into the other 
gene partner, or vice versa. Gene fusions involving FARP1 have been reported in multiple 
cancers, including lung adenocarcinoma, breast adenocarcinoma and lower grade glioma 
(http://www.tumorfusions.org). STK24 is serine/threonine protein kinase belonging to the 
mammalian Sterile20-like (MST) kinase family, key signalling molecules that regulate cell 
division cycle, cell morphogenesis, apoptosis and oncogenic transformation [50,51]. A 
caspase-dependent apoptotic role has been identified for STK24 protein [52]. The STK24 
protein is cleaved and activated by caspase-3 protein, through the STK24 regulatory 
domain, and translocated into the nucleus to promote apoptotic responses [50]. The loss 
of STK24 regulatory domain can subsequently interfere with STK24 activation and nuclear 
localisation. The FARP1-STK24 forms an in-frame fusion protein with a potential 
constitutive activation of a kinase, a phenomenon observed in gene fusions exerting 
oncogenic functionality [53]. Altogether, FARP1-STK24 may be associated with oncogenic 
properties but further investigations are required.  
Gene fusions involving protein kinases are considered potential therapeutic targets, the 
use of kinase inhibitors in tumours harbouring kinase-related gene fusions can improve 
tumour prognosis and patient outcome [54]. For example, the efficacy of using ALK 
inhibitors in advanced non–small-cell lung cancer with ALK rearrangement is evident in 
clinical trials [55]. A study by Olsen et al. [56] identified 14 inhibitors, eight of which are in 
clinical trials or are FDA approved, that inhibited the enzymatic activity of STK24. Although 
further detailed investigations are required, STK24-selective inhibitors are potential cancer 
therapeutics in tumours harbouring STK24 rearrangements.  
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Unsupervised clustering analysis of the RNA-Seq data clearly distinguished the UPSb 
samples from classical UPS as well as synovial sarcomas and osteosarcomas.  
Supervised expression profiling of UPSb versus other tumour subtypes revealed elevated 
expression of FGF23, which was confirmed in four UPSb tumours using quantitative RT-
PCR. A study by Shiba et al. (Shiba, 2016 #341) showed a highly specific 
immunohistochemical expression of FGF23 in phosphaturic mesenchymal tumours, 
whereas FGF23 expression was negative in 46 tumours, including osteosarcoma, 
chondrosarcoma and synovial sarcoma. Elevated expression of FGF23 can serve as a 
molecular marker specific to UPSb which can be diagnostically utilised in clinics. However, 
confirmation of elevated FGF23 expression in a larger UPSb cohort is recommended. FGF 
family, comprised of signalling proteins, has a role in tissue repair and tumourigenesis, by 
regulating cell proliferation, migration and angiogenesis (Feng, 2015 #340).    Promising 
curative results of a FGF23 monoclonal antibody drug, KRN23, was observed in patients 
with	 tumour-induced osteomalacia, a rare paraneoplastic syndrome clinically described by 
bone pain	fractures and muscle weakness (Florenzano, 2017 #401). Further investigations 
are necessary to confirm FGF23 targeted therapeutic opportunity in UPSb.  
An enrichment of immune response genes was identified in UPSb, which has also been 
documented in other sarcomas, including UPSst (Cancer Genome Atlas Research 
Network. Electronic address, 2017 #271). Therapeutic benefit of pembrolizumab, an 
immune checkpoint inhibitor, has been documented in 40% of UPSst cases (Tawbi, 2017 
#342). Although further investigations are needed, immune checkpoint inhibitors can be 
considered as a potential therapeutic option in UPSb patients.    
In summary, this study provides a first detailed genetic and transcriptomic alterations 
landscape of UPSb tumours, thus providing useful insights into tumourigenesis and 
broadening the understanding of this tumour subtype. We identified novel recurrent gene 
mutations in multiple cancer-related genes, including chromatin remodelling genes, that 
	 17	
are reported in UPSb tumours for the first time. We also identified novel and previously 
reported gene fusions. Several of the recurrent mutated genes and gene fusions represent 
potential druggable targets that can translate into clinics and improve patient prognosis. 
Elevated expression of FGF23 was identified, which may be a potential molecular 
biomarker for UPSb.   
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Table and Figures Legends 
Figure 1. The mutational and gene fusion landscape of UPSb. (A) Recurrent genes 
identified by whole exome sequencing in 14 tumours, grouped according to their biological 
pathway and function. (B) Gene fusions identified by RNA sequencing in eight tumours. 
CCGC: COSMIC Cancer Census Gene; DGIdb: The Drug Gene Interaction database. 
Gene described ‘cancer driving gene’ in CCGC or druggable in DGIdb are shaded in grey. 
†: TRIO is classified ‘cancer driver gene’ by IntOGen.  
Figure 2. Recurrent somatic mutations in TP53, H3F3A, ATRX and DOT1L. All the 
mutations (black balls) are missenses except for one an in-frame insertion in H3F3A. The 
relative positions of mutations are shown in the predicted protein sequence of (A) TP53, 
(B) H3F3A, (C) ATRX and (D) DOT1L. T.A.: p53 transactivation domain; T.M.: p53 
tertramerization domain; ADD: ATRX-DNMT3-DNMT3L domain; EZH2: enhancer zeste 
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homologue 2 protein (EZH2) interacting region; DAXX: death domain-associated protein 
interacting domain; ATPas: Helicase adenosine triphosphatase domain; Catalytic DOT1 
domain:  Histone-lysine N-methyltransferase DOT1 domain; STAT1: signal transducer and 
activator of transcription 1 binding motifs.  
Figure 3. The impact of the CLTC-VMP1 and FARP1-STK24 gene fusions on protein 
domain organization. The grey shaded area represents the retained protein domains of 
the fused exons of (A) CLTC-VMP1 and (B) FARP1-STK24. The gene fusion breakpoints 
are denoted by a black double slash. The CLTC-VMP1 is out of frame, reaching a 
premature stop (denoted by *) at codon 399 of VMP1 gene. The FARP1-STK24 is in-
frame, resulting from joining the first 88 and 211 amino acids of FARP1 and STK24, 
respectively. ATP B.S: ATP binding site. 
Figure 4. Unsupervised and supervised analyses of UPSb, other sarcomas and 
SRP090849 datasets using RNA-Seq data. (A) Unsupervised clustering analysis using 
Ward’s distance and 1-pearson correlation highlighted two groups of UPSb tumors (dark 
grey). UPSb_G1 samples are clearly separated from classical UPS (light grey) and 
synovial sarcomas from the SRP057793 dataset and from osteosarcomas from the 
SRP090849 dataset. UPSb_G2 samples are closer to classical UPS but remain clearly 
distinct. (B) Supervised analysis showing a violin plot of the FGF23 gene expression 
across UPSb and the different tumor types present in the SRP057793 dataset and in the 
osteosarcoma SRP090849 dataset. Individual samples are shown in circle and group 
median is represented as a black bar. (C) David Gene Ontology analyses of specific UPSb 
genes indicating a strong enrichment of immune response genes. Fold enrichment (bar 
chart) and the –log10 of the hypergeometric test P-value corrected by Bonferroni (black line 
with closed circles) are shown. 
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Material and methods supplementary information material 
Supplementary table and figure legends. 
Table S1. Coding mutational rate of UPSb.  
Table S2. Summary of the individual recurrent mutations identified in TP53 and chromatin 
remodelling genes 
Table S3. Somatic copy number alterations status of genes for which copy number 
alterations have been previously reported in UPS of bone and UPS soft tissue.  
Table S4. Summary of the eight somatic gene fusions identified by RNA-Seq. 
Figure S1. The number of somatic alterations identified in each UPSb tumour.  
Figure S2. Examples of Sanger sequencing confirmation of eight recurrent mutations 
identified by WES.  
Figure S3. Somatic copy number alteration heatmap of ten normal-tumour paired 
UPSb samples.  
Figure S4. Diagrammatic representation and validation of CLTC-VMP1 gene fusion.  
Figure S5. Schematic representation and validation of FARP1-STK24 fusion.  
Figure S6. Microscopy images of T1 and T10. 
Figure S7. Expression of FGF23 in UPSb tumours versus normal tissue samples 
using quantiative RT-PCR. 
Supplementary methods 
Tumour sample additional information 
All cases were thoroughly examined by a specialist bone tumour pathologist (VPS) to 
exclude osteosarcoma and dedifferentiated chondrosarcoma. Fresh frozen tumour sample 
was obtained from thirteen out of the fourteen cases and formalin-fixed paraffin-embedded 
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(FFPE) tissue was used in one case (T12). All tumours had matched-normal samples 
obtained from tumour-free muscle tissues adjacent to the tumour site. All samples were 
obtained from the Royal Orthopaedic Hospital NHS Foundation Trust Tumour Bank with 
informed consent from the patient and ethical approval from institutional and local 
research committee boards. Prior to the study, all patient samples were anonymised and 
used in alliance with the ethical rules and regulations presented in the Declaration of 
Helsinki. The age of the patients ranged between 24-88 years (median 64) at the time of 
diagnosis. Five patients were male and nine were female. The size of the tumours ranged 
from 3 to 12.5 cms and anatomical sites included femur, tibia, humerus and fibula. The 
morphology of tumours consisted of spindle (n=10); pleomorphic (n=1); spindle and 
epithelioid (n=2); spindle and pleomorphic (n=1) cells.  
 
WES analysis pipeline: reads mapping and variant calling 
Sequenced reads from all samples were aligned to the human genome reference 
sequence GRCh37 using BWA 0.7.x bioinformatic tool (Li, 2009 #337). Optical and PCR 
duplicates were marked with Picard 1.x (http://picard.sourceforge.net).  Somatic SNVs and 
indels were called using VarScan2 [8] and MuTect [9] tools, applying the default settings. 
Variant allele frequency (VAF) of ≥ 10% was selected for all tumours, except for one FFPE 
tumour where the VAF was adjusted to ≥20% to reduce false positive artefacts. A step-
wise filtering scheme was followed to identify likely somatic and pathogenic variants. In 
short, only nonsynonymous SNVs (missense, splice site, nonsense) and indels with ≥3 or 
≥5 supporting sequencing reads and ≥20% and ≥10% VAF, respectively, were selected. 
Variants were annotated with a modified version of Ensembl Variant Effect Predictor 
(McLaren, 2010 #339).	 Variants were manually visualised using Integrative Genomics 
Viewer (IGV) and artefactual calls were excluded. To discard potential germline 
polymorphisms, variants reported in dbSNP build 137 or the Exome Aggregation 
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Consortium (ExAc) datasets with a minor allele frequency (MAF) of >0.1% were 
eliminated. Additional rigorous steps were applied to four tumours for which matched-
normal DNA samples were not WES but were available for Sanger sequencing validation. 
In these four tumours, reported variants in dbSNP or ExAc (regardless of MAF) were 
discarded except for variants with <0.01% MAF and described somatic in COSMIC. The 
COSMIC database (http://cancer.sanger.ac.uk/cosmic) was used to highlight previously 
reported cancer mutations. SIFT and PolyPhen-2 tools were used to predict the 
pathogenic impact of missense substitutions and only variants that were predicted 
“deleterious” by at least one tool were retained. Recurrent genes were investigated in 
COSMIC Cancer Gene Census (CCGC) consortium and InTOgen database 
(https://www.intogen.org/search) to highlight potential cancer driver genes. The Drug Gene 
Interaction Database (DGIdb) was used to identify potential druggable genes 
(http://www.dgidb.org).  
WES variant validation by standard PCR and Sanger sequencing 
DNA of the tumour and adjacent normal tissue from the same patient was amplified by 
PCR (primer sequences are available upon request) targeting the genomic regions 
flanking the variant. PCR products were purified using microCLEAN (Microzone, 
Stourbridge, UK). Sequencing reactions were performed using the BigDye v3.1 cycle 
sequencing kit and sequenced on an ABI 3730 DNA analyser (Applied Biosystems, 
California, USA), following manufacture’s guidelines. 
 
 
RNA Sequencing analysis pipeline: candidate gene fusion identification 
Briefly, cDNA libraries were constructed using the Neoprep stranded mRNA library prep 
(Illumina, NP-202-1001), according to manufacturer’s protocol. Prepared libraries were 
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sequenced on NextSeq 500/550 High Output (Illumina) to produce paired-end reads (75bp 
in length).  Mapping and alignment of sequenced reads to the human genome reference 
sequence GRCh37 was achieved using the Tuxedo Suite (Trapnell, 2012 #338). 
Candidate gene fusions were called using TopHat2 [10] and STAR-Fusion fusion-junction 
mappers [11]. A series of filtering and prioritisation steps were followed to identify genuine 
fusion calls. A ‘putative’ gene fusion required a minimum of three reads supporting fusion 
junction (flanking right and left sides of the fusion). Gene fusions where both fusion 
partners are intronic or in intergenic regions were excluded as they can be DNA 
contaminants or unspliced mRNA precursors. Gene fusions were manually inspected and 
candidate gene fusions with uniform distribution of fusion junction supporting reads were 
prioritised.  
Gene fusion validation by RT-PCR, LR-PCR and Sanger Sequencing  
The total RNA was used to generate cDNA using SensiFAST cDNA Synthesis Kit (Bioline, 
UK), following the manufacturer’s instructions. The reverse transcription PCR (RT-PCR) 
reactions were assembled as following: PCR reaction buffer (50 mM Tris/HCl, 10 mM KCl, 
5 mM (NH4)2SO4, 2 mM MgCl2), 2.5mM of dNTPs, 0.5U of Fast Start DNA polymerase 
(Roche, Burgess Hill, UK) and 20 pmole of each forward and reverse primers flanking 
fusion breakpoints for 35 cycles. Genomic breakpoints analysis, through genome walking, 
was carried out by long range PCR (LR-PCR) using PrimeSTAR GXL DNA polymerase kit 
(Takara, USA). LR-PCR reaction was assembled as following: 10µl of 5X PrimeSTAR GXL 
buffer, 200 µM of dNTPs, 0.2 µM of each forward and reverse primers, 1.25 U PrimeSTAR 
GXL DNA polymerase enzyme and 50ng DNA template. LR-PCR products were amplified 
using a two-step PCR programme: 10 seconds at 98°C and 10 minutes at 60°C for 30 
cycles. All RT-PCR and LR-PCR primers are available upon request. Somatic status 
assessment of gene fusions by RT-PCR and LR-PCR was conducted on both tumour and 
match-normal nucleic acids. PCR products were visualized using 1-2% (w/v) agarose gel 
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(Bioline, UK). Purified PCR products were cleaned and Sanger sequenced as mentioned 
above. 
 
Quantitative RT-PCR analysis of FGF23 
qRT-PCR analysis was performed using Taqman gene expression assays for FGF23 
(Hs00221003_m1) and GAPDH (Hs02786624_g1) (Thermofisher Scientific, UK) according 
to manufacturer’s instructions. cDNA was generated using a High Capacity cDNA Reverse 
Transcription Kit (Multiscribe Reverse Transcriptase, Applied Biosystems, California, US) 
following the manufacturer's protocol. The mRNA level of FGF23 in the sample was 
determined following a real-time PCR reaction on a QuantoStudio 6 Flex Real-Time PCR 
system (Applied Biosystems, California, US) for a 20 µL reaction using TaqMan gene 
expression assays (20X primers and probe) and Gene Expression Master Mix (2X 
TaqMan Universal mix) (all by Applied Biosystems). Gene expression was normalized for 
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Figure 1: The mutational and gene fusion landscape of UPSb. (A) Recurrent genes 
identified by whole exome sequencing in 14 tumours, grouped according to their biological 
pathway and function. (B) Gene fusions identified by RNA sequencing in eight tumours. 
CCGC: COSMIC Cancer Census Gene; DGIdb: The Drug Gene Interaction database. 
Gene described ‘cancer driving gene’ in CCGC or druggable in DGIdb are shaded in grey. 
† TRIO is classified as ‘cancer driver gene’ by IntOGen.	
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